Net Cash Provided by (Used in) Financing Activities of ENANTA PHARMACEUTICALS INC from 30 Sep 2011 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Summary
ENANTA PHARMACEUTICALS INC quarterly and annual Net Cash Provided by (Used in) Financing Activities in USD history and change rate from 30 Sep 2011 to 31 Dec 2025.
  • ENANTA PHARMACEUTICALS INC Net Cash Provided by (Used in) Financing Activities for the quarter ending 31 Dec 2025 was $64,136,000.
  • ENANTA PHARMACEUTICALS INC annual Net Cash Provided by (Used in) Financing Activities for 2025 was $26,618,000, a 3.6% increase from 2024.
  • ENANTA PHARMACEUTICALS INC annual Net Cash Provided by (Used in) Financing Activities for 2024 was $27,626,000, a 114% decline from 2023.
  • ENANTA PHARMACEUTICALS INC annual Net Cash Provided by (Used in) Financing Activities for 2023 was $198,126,000, a 889% increase from 2022.
Source SEC data
View on sec.gov
Net Cash Provided by (Used in) Financing Activities, Quarterly (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Quarterly Change (%)
Net Cash Provided by (Used in) Financing Activities, Annual (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Annual Change (%)

ENANTA PHARMACEUTICALS INC Quarterly Net Cash Provided by (Used in) Financing Activities (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $64,136,000 +$69,122,000 01 Oct 2025 31 Dec 2025 10-Q 11 Feb 2026 2026 Q1
Q4 2024 $4,986,000 +$2,364,000 +32% 01 Oct 2024 31 Dec 2024 10-Q 11 Feb 2026 2026 Q1
Q4 2023 $7,350,000 -$7,651,000 -2542% 01 Oct 2023 31 Dec 2023 10-Q 12 Feb 2025 2024 Q1
Q4 2022 $301,000 -$9,331,000 -97% 01 Oct 2022 31 Dec 2022 10-Q 08 Feb 2024 2024 Q1
Q4 2021 $9,632,000 +$9,333,000 +3121% 01 Oct 2021 31 Dec 2021 10-Q 08 Feb 2023 2023 Q1
Q4 2020 $299,000 -$867,000 -74% 01 Oct 2020 31 Dec 2020 10-Q 10 Feb 2022 2022 Q1
Q4 2019 $1,166,000 +$26,000 +2.3% 01 Oct 2019 31 Dec 2019 10-Q 09 Feb 2021 2021 Q1
Q4 2018 $1,140,000 +$723,000 +173% 01 Oct 2018 31 Dec 2018 10-Q 10 Feb 2020 2020 Q1
Q4 2017 $417,000 01 Oct 2017 31 Dec 2017 10-Q 08 Feb 2019 2019 Q1
Q4 2013 $89,000 +$1,409,000 01 Oct 2013 31 Dec 2013 10-Q 13 Feb 2014 2014 Q1
Q4 2012 $1,320,000 01 Oct 2012 31 Dec 2012 10-Q 13 Feb 2014 2014 Q1

ENANTA PHARMACEUTICALS INC Annual Net Cash Provided by (Used in) Financing Activities (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $26,618,000 +$1,008,000 +3.6% 01 Oct 2024 30 Sep 2025 10-K 19 Nov 2025 2025 FY
2024 $27,626,000 -$225,752,000 -114% 01 Oct 2023 30 Sep 2024 10-K 19 Nov 2025 2025 FY
2023 $198,126,000 +$178,093,000 +889% 01 Oct 2022 30 Sep 2023 10-K 19 Nov 2025 2025 FY
2022 $20,033,000 +$16,953,000 +550% 01 Oct 2021 30 Sep 2022 10-K 27 Nov 2024 2024 FY
2021 $3,080,000 -$5,903,000 -66% 01 Oct 2020 30 Sep 2021 10-K 22 Nov 2023 2023 FY
2020 $8,983,000 +$6,409,000 +249% 01 Oct 2019 30 Sep 2020 10-K 23 Nov 2022 2022 FY
2019 $2,574,000 -$1,835,000 -42% 01 Oct 2018 30 Sep 2019 10-K 24 Nov 2021 2021 FY
2018 $4,409,000 +$3,392,000 +334% 01 Oct 2017 30 Sep 2018 10-K 25 Nov 2020 2020 FY
2017 $1,017,000 -$1,688,000 -62% 01 Oct 2016 30 Sep 2017 10-K 27 Nov 2019 2019 FY
2016 $2,705,000 01 Oct 2015 30 Sep 2016 10-K 29 Nov 2018 2018 FY
2013 $56,911,000 +$57,820,000 01 Oct 2012 30 Sep 2013 10-K 18 Dec 2013 2013 FY
2012 $909,000 -$943,000 -2774% 01 Oct 2011 30 Sep 2012 10-K 18 Dec 2013 2013 FY
2011 $34,000 01 Oct 2010 30 Sep 2011 10-K 18 Dec 2013 2013 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.